Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

Murat Fani Bozkurt,Irene Virgolini,Sona Balogova,Mohsen Beheshti,Domenico Rubello,Clemens Decristoforo,Valentina Ambrosini,Andreas Kjaer,Roberto Delgado-Bolton,Jolanta Kunikowska,Wim J. G. Oyen,Arturo Chiti,Francesco Giammarile,Stefano Fanti
DOI: https://doi.org/10.1007/s00259-017-3728-y
2017-05-25
Abstract:Purpose & MethodsNeuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms.Results & ConclusionThe previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
What problem does this paper attempt to address?